Still far too cheap even though it's in the could be status imho
Personally I rate their chances of success as high. But it's the size of the realistic potential that is enormous.
The reward is far far greater than the risk here imho
But we don't even have to think about commercial success yet, the risk for large pharma that imu poses right now is huge, and that will dictate the short term value imho.
Add to My Watchlist
What is My Watchlist?
